RnRMarketResearch.com adds “EpiCast Report: Age-Related Macular Degeneration – Epidemiology Forecast to 2023” to its store. The total prevalent cases of AMD in the 7MM will increase from 55,770,401 cases in 2013 to 66,069,370 cases in 2023, at a growth rate of 18.5% over the forecast period.
GlobalData epidemiologists forecast that the total prevalent cases of AMD in the 7MM will increase from 55,770,401 cases in 2013 to 66,069,370 cases in 2023, at a growth rate of 18.5% over the forecast period. Throughout the forecast period, the US will have the highest number of total prevalent cases of AMD, followed by Japan.
GlobalData’s epidemiological analysis is supported by the use of total prevalence data from epidemiological studies published in peer-reviewed journals. GlobalData epidemiologists used uniform methodology across the markets to forecast the total prevalent cases of AMD. GlobalData epidemiologists segmented AMD by stages (early AMD and late AMD, and the late AMD subtypes: dry AMD and wet AMD), which allows for a meaningful comparison of the disease populations between markets.
Age-related macular degeneration (AMD) is a progressive eye condition caused by the gradual deterioration of the macula, which is the area of the retina responsible for central vision. AMD is the most common cause of significant irreversible vision loss among the elderly in the developed countries. In addition to the high prevalence of the condition, AMD is associated with severe disability and has a major impact on the quality of life and emotional well-being of an affected individual. AMD is classified into two stages: early AMD and late AMD. Late AMD is the advanced stage of AMD, which is further subclassified as dry AMD (geographic atrophy) and wet AMD (neovascular).
- The Age-related Macular Degeneration (AMD) EpiCast Report and EpiCast Model provide an overview of the risk factors, comorbidities, and the global and historical trends for AMD in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the total prevalent cases of AMD segmented by sex and age (50–59 years, 60–69 years, 70–79 years, and =80 years) in these markets. Additionally, GlobalData epidemiologists provide the total prevalent cases of AMD segmented by AMD stages: early AMD and late AMD, as well as the late AMD subtypes: dry AMD and wet AMD.The AMD epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
- The EpiCast Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.
Order a Purchase copy @ http://www.rnrmarketresearch.com/contacts/purchase?rname=211287 .
Reasons to Buy
- Develop business strategies by understanding the trends shaping and driving the global AMD market.
- Quantify patient populations in the global AMD market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for AMD therapeutics in each of the markets covered.
Table of Contents
1 Table of Contents 1
1.1 List of Tables 3
1.2 List of Figures 3
2 Executive Summary 4
3 Introduction 5
3.1 Catalyst 5
3.2 Related Reports 7
3.3 Upcoming Reports 7
4 Epidemiology 7
4.1 Disease Background 7
4.2 Risk Factors and Comorbidities 8
4.3 Global Trends 9
4.3.1 US 9
4.3.2 5EU 10
4.3.3 Japan 10
4.4 Forecast Methodology 11
4.4.1 Sources Used 12
4.4.2 Forecast Assumptions and Methods 14
4.5 Epidemiological Forecast for AMD (2013–2023) 18
4.5.1 Total Prevalent Cases of AMD 18
4.5.2 Age-Specific Total Prevalent Cases of AMD 19
4.5.3 Sex-Specific Total Prevalent Cases of AMD 21
4.5.4 Age-Standardized Total Prevalence of AMD 23
4.5.5 Total Prevalent Cases of AMD by Stage 24
4.5.6 Total Prevalent Cases of Late AMD by Subtype 26
4.6 Discussion 28
4.6.1 Epidemiological Forecast Insight 28
4.6.2 Limitations of the Analysis 29
4.6.3 Strengths of the Analysis 30
5 Appendix 30
5.1 Bibliography 30
5.2 About the Authors 33
5.2.1 Epidemiologists 33
5.2.2 Reviewers 33
5.2.3 Acting Director of Epidemiology 34
5.2.4 Global Head of Healthcare 35
5.3 About GlobalData 36
5.4 About EpiCast 36
5.5 Contact Us 36
5.6 Disclaimer 37